HIV infection, hepatitis C infection, and HAART: Hard clinical choices

JAMA

Volumn 292, Issue 2, 2004, Pages 243-250

  Kottilil, Shyam ^a   Polis, Michael A ^a   Kovacs, Joseph A ^b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MSC 1662   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; MULTIVITAMIN; NELFINAVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A;

ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER BIOPSY; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; SUBSTANCE ABUSE; SUPERINFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ADULT; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; GENETICS; PATHOLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 3042809998     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.2.243     Document Type: Article

References (60)

1. Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 2002;4:224-232.
2. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22:696-699.
3. Kottilil S, McLaughlin M, Yang, et al. Virologic, biochemical, and histologic response to peginterferon alpha 2b and ribavirin among HCV/HIV co-infected individuals. Paper presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 16, 2003; Chicago, Ill. Abstract V1727.
4. Kottilil S, McLaughlin M, Sidorov I, et al. Early HCV kinetics predicts response to peginterferon-alpha 2b and ribavirin anti-HCV therapy among HIV co-infected individuals. Paper presented at: 2nd International AIDS Conference on the Pathogenesis of HIV Infection; July 16, 2003; Paris, France. Abstract 212.
5. US Food and Drug Administration. HIV/AIDS historical time line, 2000-2003. Available at: http://www.fda.gov/oashi/aids/miles20.html. Accessed June 5, 2004.
6. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36-43.
7. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis. 2004;38(suppl 2):S49-55.
8. Jain MK, Skiest DJ, Cloud JW, et al. Changes in mortality related to human immunodeficiency virus infection. Clin Infect Dis. 2003;36:1030-1038.
9. Selik RM. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-2000. Paper presented at: National HIV Prevention Conference; July 29, 2003; Atlanta, Ga, Abstract t1-B0202.
10. Selik RM, Byers RH, Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29:378-387.
11. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS. 1998;12:1256.
12. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity: a challenge for the hepatologist? J Hepatol. 2002;36:283-294.
13. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C. AIDS. 2004; 18:767-774.
14. Melvin DC, Lee JK, Belsey E, et al. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS. 2000;14:463-465.
15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
16. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Hepatology. 2002; 35:182-189.
17. Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy. Pharmacotherapy. 2002; 22:1468-1478.
18. Fonquernie L, Meynard JL, Charrois A, et al. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis. 2001; 32:297-299.
19. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201-S209.
20. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426-431.
21. Lebovics E, Dworkin BM, Heier SK, Rosenthal WS. The hepatobiliary manifestations of human immunodeficiency virus infection. Am J Gastroenterol. 1988; 83:1-7.
22. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities. Clin Infect Dis. 2004;38(suppl 2):S65-S72.
23. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis. 2002; 13:47-54.
24. Poles MA, Lew EA, Dieterich DT. Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterol Clin North Am. 1997;26:291-321.
25. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis. 1994;18: 339-347.
26. Pham T-V LS, Kaplowitz N. Acetaminophen Hepatotoxicity. 2nd ed. Baltimore, Md: Williams & Wilkins; 1997.
27. Boelsteri UA. Mechanisms of NSAID-induced hepatotoxicity. Drug Saf. 2002;25:633-648.
28. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. J Acquir Immune Defic Syndr. 2002;29:41-48.
29. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(suppl 2):S80-S89.
30. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23:183-194.
31. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(suppl 2): S90-S97.
32. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:831-837.
33. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002;16:2165-2173.
34. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine. Ann Intern Med. 2000;133:192-196.
35. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001;98:12671-12676.
36. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessed May 31, 2004.
37. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998;29:306-309.
38. Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15:599-603.
39. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
40. Zoulim F. A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection. Drug Saf. 2002;25:497-510.
41. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS. 2003;17:F7-F10.
42. Miller MD, Margot NA, Lamy PD, et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy. J Acquir Immune Defic Syndr. 2001;27:450-458.
43. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy. AIDS. 2000;14:F25-F32.
44. Beld M, Sentjens R, Rebers S, et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum. J Clin Microbiol. 2002;40:788-793.
45. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17: 1023-1028.
46. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-739.
47. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients. Hepatology. 2001;34:283-287.
48. Olga OZ, Nikolai DY. Invasive and non-invasive monitoring of hepatitis C virus-induced liver fibrosis. Curr Pharm Biotechnol. 2003;4:195-209.
49. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38:481-492.
50. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet. 2001;358:958-965.
51. Chung RT, Andersen J, Volberding P, et al. A randomized, controlled trial of PEG-interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 10, 2004; San Francisco, Calif. Abstract 110.
52. Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al. Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alfa-2a + ribavirin vs interferon-alfa-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 10, 2004; San Francisco, Calif. Abstract 112.
53. Perronne C, Carrat F, Bani-Sadr F, et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 10, 2004; San Francisco, Calif. Abstract 117LB.
54. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS, 2004;18:1-12.
55. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection. 1998;26:16-19.
56. Lessells R, Leen C. Management of hepatitis B in patfents coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis. 2004;23: 366-374.
57. Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient. Clin Infect Dis. 2003; 37:1678-1685.
58. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis. 2004;38 (suppl 2):S98-S103.
59. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004: 2:266-272.
60. Leen CL. Hepatitis C and HIV co-infection. Int J STD AIDS. 2004;15:289-295.